Vascular Protection in Diabetic Stroke: Role of Matrix Metalloprotease-Dependent Vascular Remodeling
暂无分享,去创建一个
A. Ergul | S. Fagan | Roshini Prakash | Maribeth H. Johnson | Weiguo Li | S. Ogbi | M. Elgebaly | E. Mezzetti | Mostafa M Elgebaly
[1] 入江 潤一郎,et al. Glucose control and vascular complications in veterans with type 2 diabetes , 2009 .
[2] A. Ergul,et al. Adaptive Cerebral Neovascularization in a Model of Type 2 Diabetes , 2009, Diabetes.
[3] E. Kilpatrick,et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control , 2009, International journal of clinical practice.
[4] K. Norga,et al. Expanding roles for AMP‐activated protein kinase in neuronal survival and autophagy , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.
[5] G. Dhar. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians. , 2009, Canadian family physician Medecin de famille canadien.
[6] H. Elewa,et al. Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.
[7] D. Federman,et al. Implications of New Diabetes Treatment Trials: Should Current Clinical Practice be Altered? , 2009, Postgraduate medicine.
[8] H. Schatz. [2008--The year of the big studies about the therapy of type-2-diabetes. ACCORD, ADVANCE, VADT, and the UKPDS 10-year follow-up data]. , 2009, MMW, Fortschritte der Medizin.
[9] L. McCullough,et al. Sex Differences in Minocycline-Induced Neuroprotection after Experimental Stroke , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] A. Dorrance,et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.
[11] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[12] B. Howard,et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.
[13] H. Lebovitz. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance. , 2008, Journal of the Indian Medical Association.
[14] H. Elewa,et al. Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study , 2008, Journal of Pharmacology and Experimental Therapeutics.
[15] S. Correia,et al. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).
[16] L. Gnudi,et al. ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] E. Lo,et al. A new penumbra: transitioning from injury into repair after stroke , 2008, Nature Medicine.
[18] Askiel Bruno,et al. Treatment of Hyperglycemia In Ischemic Stroke (THIS): A Randomized Pilot Trial , 2008, Stroke.
[19] M. Grant,et al. Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat. , 2008, European journal of pharmacology.
[20] Sumit R. Majumdar,et al. Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous Thrombolysis , 2008, Diabetes Care.
[21] J. Switzer,et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes , 2007, BMC neurology.
[22] A. Dorrance,et al. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[23] Yiqian Zhu,et al. Matrix Metalloproteinase-9 Inhibition Attenuates Vascular Endothelial Growth Factor-Induced Intracerebral Hemorrhage , 2007, Stroke.
[24] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[25] D. Pomp,et al. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. , 2007, Physiological genomics.
[26] V. Perkovic,et al. ADVANCE: breaking new ground in type 2 diabetes , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[27] D. Hess,et al. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke , 2006, BMC Neuroscience.
[28] Thomas Krucker,et al. New polyurethane‐based material for vascular corrosion casting with improved physical and imaging characteristics , 2006, Microscopy research and technique.
[29] I. Idris,et al. Diabetes mellitus and stroke , 2005, International journal of clinical practice.
[30] Michael Brownlee,et al. The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.
[31] Giuseppe Pennisi,et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease , 2005, Vascular medicine.
[32] J. Arenillas,et al. Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage: Relationship to Clinical and Radiological Outcome , 2004, Stroke.
[33] E. Schiffrin,et al. Persistent Remodeling of Resistance Arteries in Type 2 Diabetic Patients on Antihypertensive Treatment , 2004, Hypertension.
[34] R. Knight,et al. Single slice method for quantification of hemorrhagic transformation using direct ELISA , 2004, Neurological research.
[35] P. Chan,et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Mulvany,et al. The myogenic response: established facts and attractive hypotheses. , 1999, Clinical science.
[37] M. Nelson,et al. Increased myogenic tone and diminished responsiveness to ATP-sensitive K+ channel openers in cerebral arteries from diabetic rats. , 1997, Circulation research.
[38] M. Cipolla,et al. High glucose concentrations dilate cerebral arteries and diminish myogenic tone through an endothelial mechanism. , 1997, Stroke.
[39] R. Myers,et al. Hemorrhagic infarct conversion in experimental stroke. , 1992, Annals of emergency medicine.
[40] M. Zimowska,et al. [Structure and function of matrix metalloproteinases]. , 2009, Postepy biochemii.
[41] P. Weinstein,et al. Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.
[42] K. Gabbay,et al. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.